{"filing":{"accession_number":"0001339970-26-000042","cik":"0001339970","ticker":"ATYR","company_name":"aTYR PHARMA INC","form":"8-K","filing_date":"2026-07-31","report_date":"2026-07-30","primary_document":"atyr-20260730.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1339970/000133997026000042/atyr-20260730.htm"},"events":[{"id":22449,"run_id":20308,"accession_number":"0001339970-26-000042","anchor_item_number":"1.02","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The filing discloses termination of a material collaboration and license agreement with Kyorin Pharmaceutical. The termination results in reversion of exclusive rights to develop and commercialize efzofitimod in Japan back to aTyr, effectively restoring global rights to the company. This represents a material change in the company's asset portfolio and development rights, triggering Item 1.02 (Termination of a Material Definitive Agreement) and affecting the registrant's strategic position and commercial prospects.","company_name":"aTYR PHARMA INC","ticker":"ATYR","filing_date":"2026-07-31","form":"8-K","submitted_at":null,"items":[{"id":22391,"accession_number":"0001339970-26-000042","item_number":"1.02","item_title":"Termination of a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The filing discloses termination of a material collaboration and license agreement with Kyorin Pharmaceutical. The termination results in reversion of exclusive rights to develop and commercialize efzofitimod in Japan back to aTyr, effectively restoring global rights to the company. This represents a material change in the company's asset portfolio and development rights, triggering Item 1.02 (Termination of a Material Definitive Agreement) and affecting the registrant's strategic position and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T00:21:48.158985+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22391,"accession_number":"0001339970-26-000042","item_number":"1.02","item_title":"Termination of a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The filing discloses termination of a material collaboration and license agreement with Kyorin Pharmaceutical. The termination results in reversion of exclusive rights to develop and commercialize efzofitimod in Japan back to aTyr, effectively restoring global rights to the company. This represents a material change in the company's asset portfolio and development rights, triggering Item 1.02 (Termination of a Material Definitive Agreement) and affecting the registrant's strategic position and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T00:21:48.158985+00:00","company_name":"aTYR PHARMA INC","ticker":"ATYR","filing_date":"2026-07-31"}]}